report ep ahead consensu w/ in-lin rev book
beat consensu although ep guid bit light revenue book outlook
line re-affirmed increment posit cost optim
appear track enter biopharma/payor market futur growth driver
view valuat fair rel n-t growth
compani report streetaccount thomson eikon cowen compani
total revenu repres growth y/i line consensu
geographi domest revenu y/i intern revenu
roughli flat y/i grew mid-singl digit constant currenc basi
adj oper profit line consensu oper margin
despit in-lin oper result report adj ep ahead consensu
vs due lower expect tax
book y/i exceed expect y/i declin
book due higher level l-t book due part management decis
select low-margin l-t contract opportun l-t book repres
total book quarter compar last year
full year guidanc management re-affirmed revenu guidanc
adj ep guidanc
guidanc management provid revenu guidanc
in-line consensu adj ep guidanc fell short
consensu expect think due lack meaning impact
cost optim management expect book
bracket consensu
pleas see page report import disclosur
continu see best class demonstr strong histor consist
result still view lead player hcit sector continu increas
share market posit management focu drive oper effici
uncertain whether come expens top-lin growth could potenti
hinder achiev revenu compound-annual-growth-rate
progress achiev adj oper
formal launch biopharma/payor
updat va work order
implement dod contract
expans emerg market
top-lin growth
book growth y/i
oper margin
digit driven better expect
sale growth low-singl digit due
slower implement time
oper margin
lead provid inform technolog solut hospit healthcar
provid primarili solut implement stand-alon combin
enterprise-wid system design provid clinic financi inform
manag tool healthcar marketplac system design suppli
appropri health inform knowledg provid real-tim basi
compani also offer wide array servic includ implement train remot
host oper manag servic revenu cycl servic support mainten
health center employe well program third-parti administr servic
follow result increment posit appear
management track cost optim effort achiev adj oper margin target
respect believ management strategi
enter adjac market help drive top-lin growth management provid updat
cost optim effort identifi cost optim initi
expect provid benefit three wave first wave expect follow
second wave middl third wave second-half
beyond term growth opportun find management strategi provid curat
data biopharma payor actuari interest stakehold look
real-world data improv care lower cost area explor
number compani like think area still earli
stage like prove signific growth opportun mani player
high-growth profil space like life science/payor give us increas confid
achiev management revenu compound-annual-growth-rate target concern
abil maintain rang time focus adj oper
margin target set part cooper agreement starboard
addit better expect book quarter line book
guidanc like reassur investor begin express concern regard
top-lin growth particularli given fact book guidanc less long-term
book year-ago said remain sidelin think
improv outlook compani larg reflect current valuat
rais revenu estim
respect also modestli rais adj ep estim
respect rais price target
base revis dcf analysi impli share trade
amount million expect per share data
compani report cowen compani
changevariancesystem gross margin client oper incom incom tax incom min inc cont op ex-opt incom acquisition-rel option gain tax effect pre-tax wtd averag cont op ex-opt cowen
amount million expect per share data
compani report cowen compani
model assumptionstermin growth tax depreci chang work pv npv free npv futur excess valu total number valu per year end decemb cowen
amount million expect per share data
compani report cowen compani
support total gross gross margin client oper oper oper incom interest incom pre-tax pre-tax incom tax incom min minor interest- net inc cont op ex-opt net incom acquisition-rel stock option expens net net incom stock option non-recurring gain net fd wtd averag ep cont op ex-opt chang incom cont cont op ex-opt option year decemb cowen
amount million expect per share data
compani report cowen compani
gross gross margin client oper oper oper incom incom pre-tax pre-tax incom tax incom min minor interest- net inc cont op ex-opt net incom acquisition-rel stock option non-recurring gain incom tax effect pre-tax net fd wtd averag ep cont op ex-opt chang incom cont cont op ex-opt cowen
amount million
compani report cowen compani
q/q q/q q/q q/q q/q q/q q/q cost total gross total gross y/i basi cowen
amount million
compani report cowen compani
asset short-term account prepaid expens current pp softwar develop cost goodwil intang long-term total current liabil account current portion long-term defer accru payrol tax accru current long-term defer incom defer minor interest- stockhold equiti common addit paid-in retain less share accumul comprehens total stockhold total liabil stockhold short-term liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total ratio return averag total asset averag stockhold equiti cowen
amount million
compani report cowen compani
income/ loss flow oper activ depreci share base compens charg reorg busi charges- sale invest businesses- defer incom bad debt expense- invest impair other- chang oper asset liabil account prepaid expens account accru incom defer current asset net cash oper acquisit properti acquisit capit softwar develop issuanc common stock- purchas treasuri dividend common stock- proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari oper capit owner financ non-recur year end decemb cowen
amount million
compani report cowen compani
flow oper activ net adjust reconcil net incom depreci share base compens provis defer incom chang oper asset liabil net acquisit account prepaid expens account accru incom defer current asset net cash provid oper flow invest activ purchas captial purchas acquist busi net net increase/ decreas short-term capit softwar develop net cash use invest flow financ activ financ receivables- proce issuanc long-term debt- proce revolv line credit- repay revolv credit long-term proce sale common stock- proce third parti warrants- excess tax benefit share base purchas treasuri proce exercis associ stock purchas plan discounts- conting consider payment acquisit net cash provid financ eign currenc translat increas cash consolid variabl interest entitynet increas decreas equival begin equival end year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ hcit space signific amount
spend hcit driven govern relat program high-tech act
slowdown cut program could neg impact spend hcit
constrain hospit budget could potenti lead decreas hcit-rel
invest custom loss result facil consolid inpati
outpati market could creat challeng number vendor greater price
competit hcit industri current focu meaning use incent
could delay purchas decis non-ehr relat solut servic
manag expect well set strong reason guidanc
often exceed howev low expect margin expans could provid upsid
long-term top-lin growth could expect due slower adopt
popul health cloud-bas servic slower transit saa base model
rate new client win could slower expect result book
